ProSomnus (OSA) News & Sentiment

Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovation Dr. Wimms brings extensive industry and clinical development experience in sleep medicine innovation

BERN, Switzerland--(BUSINESS WIRE)-- #5G--Adtran today announced that Switzerland's Federal Institute of Metrology METAS has successfully deployed its OSA 3300 HP, improving national timekeeping performance and supporting critical scientific research. As the industry's first high-performance optical cesium atomic clock, the OSA 3300 HP sets new standards for accuracy and stability, while assuring 10 years of operation. It also strengthens Switzerland's contribution to Universal Time Coordinated (UTC).

In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as defined by apnea-hypopnea index and Epworth Sleepiness Scale measures Lilly submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA) and will initiate submissions for other global regulatory agencies in the coming weeks INDIANAPOLIS , June 21, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo.

HUNTSVILLE, Ala.--(BUSINESS WIRE)-- #5G--Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+). As part of Adtran's Oscilloquartz portfolio of industry-first optical cesium clocks, the devices leverage unique, state-of-the-art optical pumping technology to meet evolving demands across applications from scientific res.